Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
585.285736487
InChI
InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
InChI Key
InChIKey=LKCWBDHBTVXHDL-RMDFUYIESA-N
IUPAC Name
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide
Traditional IUPAC Name
amikacin
SMILES
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
Độ hòa tan
1.85E+005 mg/L (at 25 °C)
pKa (strongest acidic)
12.1
pKa (Strongest Basic)
9.79
Refractivity
129.84 m3·mol-1
Dược Lực Học :
Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
Cơ Chế Tác Dụng :
Amikacin is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A. Similar to other aminoglycosides, amikacin disrupts bacterial protein synthesis by binding to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and tRNA acceptor sites leading to the production of non-functional or toxic peptides. Other mechanisms not fully understood may confer the bactericidal effects of amikacin. Amikacin is also nephrotoxic and ototoxic.
Aminoglycosides like Amikacin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Amikacin inhibits protein synthesis by binding to the 30S ribosomal subunit to prevent the formation of an initiation complex with messenger RNA. Specifically Amikacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
Dược Động Học :
▧ Absorption :
Rapidly absorbed after intramuscular administration. Rapid absorption occurs from the peritoneum and pleura. Poor oral and topical absorption. Poorly absorbed from bladder irrigations and intrathecal administration.
▧ Volume of Distribution :
* 24 L [normal adult subjects]
▧ Protein binding :
0-11%
▧ Route of Elimination :
Amikacin is excreted primarily by glomerular filtration.
▧ Half Life :
2-3 hours
▧ Clearance :
* 100 mL/min
Độc Tính :
Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Amikacin accumulates in proximal renal tubular cells. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy.
May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance.
Chỉ Định :
For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species. Amikacin may also be used to treat Mycobacterium avium and Mycobacterium tuberculosis infections.
Tương Tác Thuốc :
-
Atracurium
The agent increases the effect of muscle relaxant
-
Bumetanide
Increased ototoxicity
-
Cefalotin
Increased risk of nephrotoxicity
-
Cefamandole
Increased risk of nephrotoxicity
-
Cefapirin
Increased risk of nephrotoxicity
-
Cefazolin
Increased risk of nephrotoxicity
-
Cefonicid
Increased risk of nephrotoxicity
-
Cefoperazone
Increased risk of nephrotoxicity
-
Ceforanide
Increased risk of nephrotoxicity
-
Cefotaxime
Increased risk of nephrotoxicity
-
Cefotetan
Increased risk of nephrotoxicity
-
Cefoxitin
Increased risk of nephrotoxicity
-
Cefradine
Increased risk of nephrotoxicity
-
Ceftazidime
Increased risk of nephrotoxicity
-
Ceftizoxime
Increased risk of nephrotoxicity
-
Ceftriaxone
Increased risk of nephrotoxicity
-
Cefuroxime
Increased risk of nephrotoxicity
-
Cisplatin
Increased risk of nephrotoxicity
-
Colistimethate
Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.
-
Doxacurium chloride
The agent increases the effect of muscle relaxant
-
Ethacrynic acid
Increased ototoxicity
-
Furosemide
Increased ototoxicity
-
Metocurine
The agent increases the effect of muscle relaxant
-
Mivacurium
The agent increases the effect of muscle relaxant
-
Pancuronium
The agent increases the effect of muscle relaxant
-
Pipecuronium
The agent increases the effect of muscle relaxant
-
Rocuronium
The agent increases the effect of muscle relaxant
-
Succinylcholine
The agent increases the effect of muscle relaxant
-
Tacrolimus
Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy.
-
Thalidomide
Thalidomide increases the renal toxicity of the aminoglycoside
-
Ticarcillin
Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line.
-
Torasemide
Increased ototoxicity
-
Tubocurarine
The agent increases the effect of muscle relaxant
-
Vecuronium
The agent increases the effect of muscle relaxant
Liều Lượng & Cách Dùng :
Liquid - Intravenous
Dữ Kiện Thương Mại
Nhà Sản Xuất
-
Sản phẩm biệt dược : Amexel
-
Sản phẩm biệt dược : Amikin
-
Sản phẩm biệt dược : Amukin
-
Sản phẩm biệt dược : Biklin
-
Sản phẩm biệt dược : Erkacin
-
Sản phẩm biệt dược : Farcyclin
-
Sản phẩm biệt dược : Flexelite
-
Sản phẩm biệt dược : Kamin
-
Sản phẩm biệt dược : Novamin
-
Sản phẩm biệt dược : Selaxa
-
Sản phẩm biệt dược : Selemycin
-
Sản phẩm biệt dược : Sikacin
-
Sản phẩm biệt dược : Tipkin
-
Sản phẩm biệt dược : Tybikin
-
Sản phẩm biệt dược : Ukaject
-
Sản phẩm biệt dược : Unikin
-
Sản phẩm biệt dược : Uzix
-
Sản phẩm biệt dược : Xylanal
Tài Liệu Tham Khảo Thêm
National Drug Code Directory